Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies

Annals of Medicine

Volumn 44, Issue 2, 2012, Pages 157-169

  Schwartz, Sherwyn L ^a  

^a Diabetes and Glandular Disease Clinic   (United States)

Author keywords

Dipeptidyl peptidase 4 inhibitor; glycemia; incretin; oral antidiabetic drugs; Saxagliptin; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATAZANAVIR; CLARITHROMYCIN; GLIBENCLAMIDE; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; METFORMIN; NEFAZODONE; NELFINAVIR; PIOGLITAZONE; PLACEBO; RITONAVIR; ROSIGLITAZONE; SAQUINAVIR; SAXAGLIPTIN; SULFONYLUREA; TELITHROMYCIN;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DEMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADAMANTANE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; RISK;

EID: 84857702144     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.603701     Document Type: Article

References (41)

1. Nathan DM, BuseJB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193-203.
2. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. EndocrPract. 2009;15:540-59.
3. Kulasa K, Edelman S. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid. 2010;5:23-37.
4. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122:16-27.
5. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardiocerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12:485-94.
6. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
7. TRADJENTA® (linagliptin). Full prescribing information. Boehringer Ingelheim Pharmaceuticals, Ridgefi eld, CT, USA; 2011.
8. JANUVIA ® (sitagliptin). Full prescribing information. Merck & Co, Whitehouse Station, NJ, USA; 2010.
9. GALVUS (vildagliptin). Prescribing information. Novartis Europharm Ltd, West Sussex, UK; 2011.
10. ONGLYZA® (saxagliptin). Full prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA; 2011.
11. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract. 2010;90:131-40.
12. KOMBIGLYZE XR® (saxagliptin and extended-release metformin hydrochloride). Full prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA; 2010.
13. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26:249-62.
14. Kirby M, Yu DMT, O' C onnor SP, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond). 2010;118:31-41.
15. Patel CG, Kornhauser D, Vachharajani N, Komoroski B, Brenner E, Handschuh Del Corral M, et al. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of 3 oral antidiabetic drugs (metformin, glyburide, or pioglitazone) in healthy subjects. Diabetes Obes Metab. 2011;13:604-14.
16. Patel CG, Girgis S, Kornhauser DM. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended release, and ketoconazole. Clin Pharmacol Adv App. 2011; 3:13-25.
17. Rosenstock J. Clinical overview of saxagliptin for type 2 diabetes management. Exp Rev Endocrinol Metab. 2010; 5:809-23.
18. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatmentnaive patients with type 2 diabetes. Curr Med Res Opin. 2009;25:2401-11.
19. Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810-9.
20. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, YuyanDuan R, Ravichandran S, et al. The effi cacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649-55.
21. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611-22.
22. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63:1395-406.
23. Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. 2010;26:2355-63.
24. NestoRW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fl uid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-63.
25. Chen R, Donovan M, Rusnak JM. Saxagliptin used as monotherapy or in combination with other antihyperglycemic agents does not signifi cantly increase risk of hypoglycemia [abstract]. Diabetes. 2009;58(suppl 1): 2082-PO. http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1& CID=74195. Accessed August 4, 2011.
26. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64:1619-31.
27. ScheenAJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Effi cacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540-9.
28. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I, et al. Saxagliptin improvesglycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011; 13:523-32.
29. AVANDIA ® (rosiglitazome maleate). Full prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA; 2011.
30. NeumillerJJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009;7:324-42.
31. GLUCOPHAGE® , GLUCOPHAGE® XR (metformin hydrochloride, extended-release metformin hydrochloride). Full prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA; 2009.
32. BYETTA ® (exenatide). Full prescribing information. Amylin Pharnaceuticals, San Diego, CA, USA; 2010.
33. PRECOSE® (acarbose). Full prescribing information. Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA; 2008.
34. Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Effi cacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011;27:863-9.
35. Maheux P, Donovan M, Allen E, Berglind N, Bouzamondo H. Effi cacy of saxagliptin in relation to baseline HbA1c in a pooled analysis of three add-on pivotal randomised phase 3 clinical trials [abstract]. European Association for the Study of Diabetes 46th Annual Meeting; 20-24 September 2010; Stockholm, Sweden.
36. Allen E, Donovan M, Berglind N, Maheux P. Effi cacy of saxagliptin according to patient baseline characteristics: a pooled analysis of 3 add-on pivotal randomised phase 3 clinical trials [abstract]. European Association for the Study of Diabetes 46th Annual Meeting; 20-24 September 2010; Stockholm, Sweden.
37. Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI 53);2011. Available at: clinicaltrials.gov/ct2/show/NCT01107886?term-NCT01107886&rank-1 (accessed 13 May 2011).
38. DeFronzo R, Hissa MN, Garber AJ, Gross JL, DuanRY, Ravichandran S, et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetes. 2009;58:547-P.
39. Hollander PL, Jia L, Frederich R, Allen E, Chen R; CV181013 Investigators. Safety and effi cacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2011;8:125-35.
40. Chacra AR, Tan GH, Ravichandran S, List J, Chen R; CV181040 Investigators. Safety and effi cacy of saxagliptin in combination with submaximal sulphonylurea versus uptitrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011;8:150-9.
41. Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011;13:567-76.